Antidepressant-like activity of a brain penetrant HCN channel inhibitor in mice
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Changes in Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) channel function have been linked to depressive-like traits, making them potential drug targets. However, there is currently no peer-reviewed data supporting the use of a small molecule modulator of HCN channels in depression treatment. Org 34167, a benzisoxazole derivative, has been patented for the treatment of depression and progressed to Phase I trials. In the current study, we analysed the biophysical effects of Org 34167 on HCN channels in stably transfected human embryonic kidney 293 (HEK293) cells and mouse layer V neurons using patch-clamp electrophysiology, and we utilised three high-throughput screens for depressive-like behaviour to assess the activity of Org 34167 in mice. The impact of Org 34167 on locomotion and coordination were measured by performing rotarod and ledged beam tests. Org 34167 is a broad-spectrum inhibitor of HCN channels, slowing activation and causing a hyperpolarising shift in voltage-dependence of activation. It also reduced Ih-mediated sag in mouse neurons. Org 34167 (0.5 mg/kg) reduced marble burying and increased the time spent mobile in the Porsolt swim and tail suspension tests in both male and female BALB/c mice, suggesting reduced depressive-like behaviour. Although no adverse effects were seen at 0.5 mg/kg, an increase in dose to 1 mg/kg resulted in visible tremors and impaired locomotion and coordination. These data support the premise that HCN channels are valid targets for anti-depressive drugs albeit with a narrow therapeutic index. Drugs with higher HCN subtype selectivity are needed to establish if a wider therapeutic window can be obtained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“chronic stress elevates HCN1 and Ih in dorsal Cornu Ammonis area 1 (CA1), reducing excitability and producing depressive behaviors”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [293]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“lowering HCN surface expression via cAMP signaling or direct HCN1 inhibition rescues stress-related cognitive deficits and post-stroke affective slowing [289,292,293]”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [293]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although a wide variety of pharmacological treatments are used to clinically manage depression, one-half to two-thirds of patients may be resistant to routinely administered antidepressants (Fava, 2003; Rush et al., 2006; Warden et al., 2007), such as tricyclic antidepressants, monoamine oxidase inhibitors and SSRIs,…”
BackgroundDepression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,696
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“Although a wide variety of pharmacological treatments are used to clinically manage depression, one-half to two-thirds of patients may be resistant to routinely administered antidepressants (Fava, 2003; Rush et al., 2006; Warden et al., 2007), such as tricyclic antidepressants, monoamine oxidase inhibitors and SSRIs,…”
BackgroundHyperpolarization-Activated Cation Channels: From Genes to Function
Biel, M., Wahl-Schott, C., Michalakis, S., & Zong, X. (2009) · Physiological Reviews · doi:10.1152/physrev.00029.2008 · Cited by 1,003
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Wong, D. T., Bymaster, F. P., & Engleman, E. A. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00209-o · Cited by 647
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580 · cited 1×
“As such, the exploration and development of novel antidepressant compounds with alternative mechanisms of action are essential for addressing the needs of these patients, especially when considering both the prevalence and the tremendous social, financial and health burdens of depression (Mrazek et al., 2014; Herrman…”
BackgroundSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2
Ludwig, A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg032 · Cited by 534
Lucki, I., Dalvi, A., & Mayorga, A. (2001) · Psychopharmacology · doi:10.1007/s002130100694 · Cited by 506
Treatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
The VGL-Chanome: A Protein Superfamily Specialized for Electrical Signaling and Ionic Homeostasis
Yu, F. H., & Catterall, W. A. (2004) · Science's STKE · doi:10.1126/stke.2532004re15 · Cited by 479
Ketamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455
HCN channels: Structure, cellular regulation and physiological function
Wahl-Schott, C., & Biel, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8525-0 · Cited by 433
Reducing the global burden of depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Kieling, C., McGorry, P., Horton, R., Sargent, J., & Patel, V. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32408-5 · Cited by 418
Cao, J.-L., Covington, H. E., Friedman, A. K., Wilkinson, M. B., Walsh, J. J., Cooper, D. C., Nestler, E. J., & Han, M.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3177-10.2010 · Cited by 402
Nolan, M. F., Malleret, G., Lee, K. H., Gibbs, E., Dudman, J. T., Santoro, B., Yin, D., Thompson, R. F., Siegelbaum, S. A., Kandel, E. R., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00884-5 · Cited by 319
HCN channels: Function and clinical implications
Benarroch, E. E. (2013) · Neurology · doi:10.1212/wnl.0b013e31827dec42 · Cited by 245
Nicolas, L. B., Kolb, Y., & Prinssen, E. P. M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.015 · Cited by 234
Treatment-resistant depression
Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 231
Treatment-Resistant Depression: Response to Low-Dose Transdermal But Not Oral Selegiline
Morgan, P. T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000270085.15253.15 · Cited by 222
Exploring HCN channels as novel drug targets
Postea, O., & Biel, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3576 · Cited by 222
The Clinical Use of Ivabradine
Koruth, J. S., Lala, A., Pinney, S., Reddy, V. Y., & Dukkipati, S. R. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.038 · Cited by 176
Feeling Strained? Influence of Genetic Background on Depression-Related Behavior in Mice: A Review
Jacobson, L. H., & Cryan, J. F. (2007) · Behavior Genetics · doi:10.1007/s10519-006-9106-3 · Cited by 167
Kim, C. S., Chang, P. Y., & Johnston, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.027 · Cited by 158
Fluoxetine: a review on evidence based medicine
Rossi, A., Barraco, A., & Donda, P. (2004) · Annals of General Hospital Psychiatry · doi:10.1186/1475-2832-3-2 · Cited by 132
Lewis, A. S., Vaidya, S. P., Blaiss, C. A., Liu, Z., Stoub, T. R., Brager, D. H., Chen, X., Bender, R. A., Estep, C. M., Popov, A. B., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0936-11.2011 · Cited by 122
Dysfunctional HCN ion channels in neurological diseases
DiFrancesco, J. C., & DiFrancesco, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00071 · Cited by 122
HCN2 Channels in Cholinergic Interneurons of Nucleus Accumbens Shell Regulate Depressive Behaviors
Cheng, J., Umschweif, G., Leung, J., Sagi, Y., & Greengard, P. (2019) · Neuron · doi:10.1016/j.neuron.2018.12.018 · Cited by 110
Santoro, B., & Shah, M. M. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023356 · Cited by 108
HCN2 channels in the ventral tegmental area regulate behavioral responses to chronic stress
Zhong, P., Vickstrom, C. R., Liu, X., Hu, Y., Yu, L., Yu, H.-G., & Liu, Q.-S. (2018) · eLife · doi:10.7554/elife.32420 · Cited by 99 · cited 2×
“Similarly, HCN2 overexpression in dopamine neurons of the ventral tegmental area was effective in reversing the depressive phenotypes caused by chronic mild unpredictable stress in mice (Zhong et al., 2018).”
BackgroundMcVey Neufeld, K.-A., Kay, S., & Bienenstock, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00294 · Cited by 79
Zobeiri, M., Chaudhary, R., Blaich, A., Rottmann, M., Herrmann, S., Meuth, P., Bista, P., Kanyshkova, T., Lüttjohann, A., Narayanan, V., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz047 · Cited by 74
Ivabradine for the Treatment of Cardiovascular Diseases
Ide, T., Ohtani, K., Higo, T., Tanaka, M., Kawasaki, Y., & Tsutsui, H. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-1184 · Cited by 73
Input resistance is voltage dependent due to activation of Ih channels in rat CA1 pyramidal cells
Surges, R., Freiman, T. M., & Feuerstein, T. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20075 · Cited by 60
Kim, C. S., Brager, D. H., & Johnston, D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.28 · Cited by 55
HCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54 · cited 1×
“Of the four isoforms, HCN1 channels have been specifically implicated in depression (Shah, 2012; Ku and Han, 2017; Kim and Johnston, 2018).”
BackgroundSamalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2030757 · Cited by 54
Han, Y., Heuermann, R. J., Lyman, K. A., Fisher, D., Ismail, Q.-A., & Chetkovich, D. M. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.99 · Cited by 53
HCN Channels: New Therapeutic Targets for Pain Treatment
Ramírez, D., Zúñiga, R., Concha, G., & Zúñiga, L. (2018) · Molecules · doi:10.3390/molecules23092094 · Cited by 52
Cation leak underlies neuronal excitability in an HCN1 developmental and epileptic encephalopathy
Bleakley, L. E., McKenzie, C. E., Soh, M. S., Forster, I. C., Pinares-Garcia, P., Sedo, A., Kathirvel, A., Churilov, L., Jancovski, N., Maljevic, S., et al. (2021) · Brain · doi:10.1093/brain/awab145 · Cited by 47
Self-citationHCN4 knockdown in dorsal hippocampus promotes anxiety‐like behavior in mice
Günther, A., Luczak, V., Gruteser, N., Abel, T. G., & Baumann, A. (2018) · Genes Brain & Behavior · doi:10.1111/gbb.12550 · Cited by 30
Paradigm shift: new concepts for HCN4 function in cardiac pacemaking
Hennis, K., Biel, M., Fenske, S., & Wahl‐Schott, C. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02698-4 · Cited by 30
Oyrer, J., Bleakley, L. E., Richards, K., Maljevic, S., Phillips, A. M., Petrou, S., Nowell, C. J., & Reid, C. A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00211 · Cited by 27
Self-citationHCN1 Channels: A New Therapeutic Target for Depressive Disorders?
Shah, M. M. (2012) · Science Signaling · doi:10.1126/scisignal.2003593 · Cited by 26
Lyman, K. A., Han, Y., & Chetkovich, D. M. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1287899 · Cited by 25
A Possible Link Between HCN Channels and Depression
Kim, C. S., & Johnston, D. (2018) · Chronic Stress · doi:10.1177/2470547018787781 · Cited by 23
Kharouf, Q., Phillips, A. M., Bleakley, L. E., Morrisroe, E., Oyrer, J., Jia, L., Ludwig, A., Jin, L., Nicolazzo, J. A., Cerbai, E., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15088 · Cited by 23
Self-citationIntracortical microinjections may cause spreading depression and suppress absence seizures
Samotaeva, I., Tillmanns, N., van Luijtelaar, G., & Vinogradova, L. V. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.013 · Cited by 22
HCN channels: New targets for the design of an antidepressant with rapid effects
Luo, P., He, G., & Liu, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.081 · Cited by 12
Characterisation of a novel antidepressant : Org 34167.
Slattery, D. A. (2003) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 4
Research works printed but not linked: 4
- AdisInsight, 2009, Drug profile: Org 34167
- 2001, Australia and New Zealand Council for the Care of animals in research and testing euthanasia of animals used for scientific Purposes
- Leysen, 1997, Substituted benzylamines and their use for the treatment of depression
- Ward, 2011, Ih Channel inhibitors for the promotion of wakefulness
Cited by
Slc35a2 mosaic knockout impacts cortical development, dendritic arborisation, and neuronal firing
Spyrou, J., Aung, K. P., Vanyai, H. K., Leventer, R. J., Maljevic, S., Lockhart, P. J., Howell, K. B., & Reid, C. A. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106657 · Cited by 17
Self-citationZhou, M., Tao, X., Lin, K., Leng, C., Yang, Y., Gui, Y., Sun, Y., Zhou, M., Sun, B., Xia, Y., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038263 · Cited by 6
“55,56 For instance, ketamine has been shown to exhibit a fast-acting anti-depressant effect by inhibiting presynaptic HCN1 channels, 57 whereas knockdown of HCN1 could increase the excitability of pyramidal neurons in the hippocampal CA1 (cornu ammonis 1) region and produce antidepressant-like…”
The Potential Antidepressant Compound Org 34167 Modulates HCN Channels Via a Novel Mode of Action
McKenzie, C. E., Hung, A., Phillips, A. M., Soh, M. S., Reid, C. A., & Forster, I. C. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000676 · Cited by 6
Self-citationMelittin protects against neural cell damage in rats following ischemic stroke
Yao, X., Kang, J., Li, Y., Zhang, H., Yang, Z., & Chen, E. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102462 · Cited by 6
Teichman, E. M., Hu, J., Lin, H.-Y., Fisher-Foye, R. L., Blando, A., Hu, X., Kaniskan, H. Ü., Montgomery, S. E., Cai, M., Parise, L. F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02972-8 · Cited by 5
“Modulation of dopamine activity through HCN channel functions has revealed its potency as a novel treatment for stress-induced behavioral and physiological alterations [19, 26, 42 – 44].”
Metadata
- Authors
- Pinares-Garcia, P., Spyrou, J., McKenzie, C. E., Forster, I. C., Soh, M. S., Mohamed Syazwan, E., Atif, M., & Reid, C. A.
- Affiliations
- The University of Melbourne (AU)
- Corresponding author
- Reid, Christopher A.
- ORCID
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-05-10
- Volume
- 14
- Pages
- 1159527-1159527
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10206048
- OpenAlex
- W4378515463
- Cited by
- 15
- References
- 54
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 2
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- National Health and Medical Research Council (10915693)
- Australian Government (Research Training Program Scholarship)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- HCN channels, benzisoxazoles, antidepressant-like effects, depression, voltage dependence of activation, depression-like behavior, tremor, therapeutic window
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.